Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) +1(332) 2424 294 (Int'l) help@24lifesciences.com
+91 9425150513 (Asia) +1(332) 2424 294 (Int'l) help@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Treatment Devices for Hemorrhoid Market was valued at US$ 847.3 million in 2024 and is projected to reach US$ 1.42 billion by 2032, at a CAGR of 6.8% during the forecast period 2025-2032. This growth aligns with the broader medical devices market which was valued at USD 603 billion in 2023, growing at 5% CAGR, as healthcare expenditure continues rising globally.
Treatment devices for hemorrhoids are specialized medical instruments designed to diagnose and treat swollen veins in the lower rectum and anus. These devices encompass various product categories including band ligators, infrared coagulators, proctoscopes & anoscopes, bipolar systems, and Doppler probes. Each serves distinct therapeutic purposes from minimally invasive procedures to surgical interventions.
The market expansion is driven by rising hemorrhoid prevalence linked to sedentary lifestyles, aging populations, and pregnancy-related cases. North America currently leads regional adoption due to advanced healthcare infrastructure, while Asia-Pacific shows fastest growth potential owing to increasing medical tourism and healthcare investments. Key players like Medtronic and Boston Scientific are enhancing product portfolios through R&D, with recent advancements focusing on outpatient procedural efficiency.
Increasing Prevalence of Hemorrhoids to Fuel Market Expansion
The global hemorrhoid treatment devices market is experiencing robust growth, primarily driven by the rising prevalence of hemorrhoidal disease across all age groups. Current epidemiological data indicates that approximately 10 million people in key markets suffer from symptomatic hemorrhoids, with prevalence rates increasing by nearly 3-4% annually due to sedentary lifestyles and poor dietary habits. The condition affects about 50% of the population above age 50, creating a substantial patient pool requiring medical intervention. This growing disease burden is compelling healthcare systems to adopt advanced treatment solutions, thereby propelling demand for innovative hemorrhoid treatment devices.
Technological Advancements in Minimally Invasive Procedures
The market is witnessing significant transformation through technological innovations in minimally invasive surgical techniques. Advanced devices such as Doppler-guided hemorrhoidal artery ligation systems and next-generation infrared coagulators are revolutionizing treatment protocols by reducing postoperative pain and shortening recovery times. The shift from traditional excisional hemorrhoidectomy to these minimally invasive procedures has been remarkable, with current adoption rates exceeding 60% in developed markets. Recent product launches featuring enhanced precision and safety profiles, such as the THD Slide device introduced in 2023, are further accelerating this transition. These technological improvements are making procedures more accessible and acceptable to patients, thereby expanding the addressable market.
Growing Preference for Outpatient Treatment Settings
The healthcare industry's paradigm shift toward ambulatory care is significantly benefiting the hemorrhoid treatment devices market. Approximately 75% of hemorrhoid procedures are now performed in outpatient settings, driven by cost-efficiency considerations and patient preference for same-day treatments. This trend is particularly pronounced in the United States and Western Europe, where ambulatory surgical centers account for nearly 40% of all hemorrhoid treatments. The development of compact, user-friendly devices specifically designed for outpatient use has been instrumental in this transition. Furthermore, reimbursement policies increasingly favor outpatient procedures, creating additional incentives for healthcare providers to adopt these treatment modalities.
High Treatment Costs and Reimbursement Challenges
Despite strong market growth prospects, the high cost of advanced hemorrhoid treatment devices presents a significant barrier to widespread adoption. Advanced ligation systems and coagulation devices can cost 3-5 times more than conventional surgical instruments, creating financial strain for healthcare facilities. In developing markets, where out-of-pocket expenditure accounts for nearly 60% of healthcare costs, these price differentials severely limit market penetration. Additionally, inconsistent reimbursement policies across regions complicate adoption decisions, with some insurers classifying certain procedures as cosmetic rather than medically necessary. This reimbursement ambiguity affects approximately 20% of potential patients who might otherwise opt for advanced treatment options.
Limited Awareness and Social Stigma
The market faces considerable challenges due to persistent social stigma surrounding hemorrhoidal disease and low awareness about modern treatment options. Surveys indicate that nearly 40% of patients delay seeking treatment due to embarrassment, with average diagnosis delays exceeding 18 months from symptom onset. This cultural barrier is particularly pronounced in certain Asian and Middle Eastern markets, where discussions about rectal health remain taboo. Furthermore, approximately 30% of general practitioners lack awareness about recent technological advancements in hemorrhoid treatment, leading to suboptimal patient referrals. These factors collectively suppress market growth by preventing timely intervention and limiting patient access to advanced treatment modalities.
Emerging Markets Present Significant Growth Potential
The hemorrhoid treatment devices market holds substantial untapped potential in emerging economies across Asia-Pacific and Latin America. These regions are experiencing rapid healthcare infrastructure development, with governments increasing healthcare expenditure by 8-10% annually. The growing middle-class population with improved healthcare access represents a market expansion opportunity exceeding $500 million in the coming years. Particularly in China and India, where hemorrhoid prevalence matches Western levels but treatment rates remain 40-50% lower, there exists significant room for market penetration. Local manufacturers are increasingly collaborating with global players to develop cost-effective solutions tailored to these price-sensitive markets.
Integration of AI and Robotics in Treatment Protocols
The incorporation of artificial intelligence and robotic assistance in hemorrhoid treatment presents a transformative opportunity for market growth. Recent developments in AI-powered diagnostic systems can analyze anorectal anatomy with 95% accuracy, enabling more precise treatment planning. Robotic-assisted hemorrhoidectomy systems, though currently representing less than 5% of procedures, are projected to grow at 25% CAGR as they demonstrate superior outcomes in complex cases. The market is also seeing increased investment in teleproctology platforms that combine remote consultation with device-assisted treatment, particularly valuable in rural and underserved areas. These technological integrations are expected to create new revenue streams while improving treatment efficacy.
Regulatory Hurdles and Compliance Requirements
The hemorrhoid treatment devices market faces increasing regulatory complexity, with average product approval timelines extending to 18-24 months in major markets. Recent changes in medical device classification systems, particularly in the European Union under MDR, have resulted in 30% of existing devices requiring reclassification and additional clinical data. In the United States, the FDA has intensified post-market surveillance, increasing compliance costs by approximately 20% for manufacturers. These regulatory challenges are particularly burdensome for small and medium-sized enterprises, potentially stifling innovation and limiting market competition.
Product Commoditization and Pricing Pressure
Intense competition in the hemorrhoid treatment devices market is leading to product commoditization and severe pricing pressures. With over 50 companies competing in the space, average selling prices have declined by 12-15% over the past three years. This trend is particularly evident in the band ligation segment, where generic alternatives now capture nearly 40% market share. The situation is exacerbated by group purchasing organizations that negotiate bulk discounts, further compressing manufacturer margins. While premium products with differentiated features maintain pricing power, the broader market faces challenges in sustaining profitability amid these competitive pressures.
The global hemorrhoid treatment devices market is experiencing significant growth due to the rising adoption of minimally invasive surgical (MIS) techniques. Procedures such as rubber band ligation, infrared coagulation, and Doppler-guided hemorrhoidal artery ligation are gaining traction because they reduce hospital stays, minimize postoperative pain, and offer faster recovery times compared to traditional hemorrhoidectomy. The market for these devices is projected to grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2032, fueled by increasing patient preference for outpatient treatments. Furthermore, advancements in disposable and single-use devices have improved infection control measures, making these treatments safer and more cost-effective for healthcare providers.
Increasing Prevalence of Hemorrhoidal Disease
The rising incidence of hemorrhoids, particularly in aging populations and sedentary lifestyles, is a major driver for market growth. Factors such as obesity, prolonged sitting, and low-fiber diets contribute to the condition, with studies indicating that nearly 50% of adults over 50 years experience symptoms at some point. Developing regions are witnessing a surge in demand for treatment devices due to increasing awareness and improving healthcare infrastructure. Governments and healthcare organizations are also launching awareness campaigns, encouraging early diagnosis and treatment, which further propels market expansion.
Recent innovations in hemorrhoid treatment devices include the development of automated ligation systems and advanced bipolar probes that enhance precision and reduce procedure times. Companies are investing in R&D to introduce smart devices with improved ergonomics and real-time monitoring capabilities. For instance, next-generation Doppler probes now offer better visualization of blood flow, reducing the risk of complications. Additionally, the integration of Artificial Intelligence (AI) in diagnostic tools is improving the accuracy of hemorrhoid classification, allowing clinicians to tailor treatments more effectively. These advancements are expected to create new growth opportunities in both developed and emerging markets.
Strategic Innovation and Expansion Define Market Competition
The global Treatment Devices for Hemorrhoid market features a moderately consolidated competitive landscape dominated by established medical technology companies with strong distribution networks and innovative product portfolios. Medtronic and Ethicon (Johnson & Johnson) currently lead the market, collectively holding approximately 35% revenue share in 2024. Their dominance stems from comprehensive offerings across band ligators, bipolar systems, and advanced surgical solutions.
Boston Scientific has emerged as a key challenger, particularly in minimally invasive treatment segments. Their recent launch of next-generation Doppler-guided hemorrhoidal artery ligation (DGHAL) devices has strengthened their position in ambulatory surgery centers. While these large players dominate high-end markets, regional specialists like THD SpA (Italy) maintain strong footholds in European markets through specialty devices.
Market participants are actively pursuing three key strategies: product line extensions in office-based treatment devices, geographic expansion into emerging Asian markets, and strategic acquisitions of niche technology developers. Recent examples include Micro-Tech Endoscopy's 2023 acquisition of a Korean proctoscope manufacturer, enhancing their APAC distribution capabilities.
Mid-sized competitors like Cook Medical and ConMed differentiate through specialized solutions - Cook's biodegradable banding systems and ConMed's integrated coagulation platforms have gained particular traction in hospital settings. Meanwhile, technological disrputors like Rocket Medical are gaining market share through AI-enhanced diagnostic proctoscopes.
Medtronic plc (Ireland)
Ethicon (Johnson & Johnson) (U.S.)
Micro-Tech Endoscopy (U.S.)
ConMed Corporation (U.S.)
Cook Medical Inc. (U.S.)
Rocket Medical plc (UK)
THD SpA (Italy)
Integra LifeSciences Corporation (U.S.)
Band Ligators Segment Leads Owing to Their Minimally Invasive Nature and High Efficacy
The market is segmented based on type into:
Band Ligators
Subtypes: Rubber Band Ligation Devices and others
Infrared Coagulators
Proctoscopes & Anoscopes
Subtypes: Disposable and Reusable
Bipolar System
Doppler Probes
Others
Hospitals and Clinics Segment Dominates Due to Increasing Professional Hemorrhoid Treatment Procedures
The market is segmented based on application into:
Hospitals and Clinics
Ambulatory Surgery Centers
Others
Minimally Invasive Technologies Gain Traction for Reduced Recovery Time and Lower Complication Rates
The market is segmented based on technology into:
Minimally Invasive Procedures
Non-Invasive Procedures
Surgical Procedures
Specialty Clinics Show Rapid Growth Due to Focused Treatment Approaches
The market is segmented based on end user into:
Specialty Clinics
General Hospitals
Ambulatory Centers
Others
North America
The North American hemorrhoid treatment devices market is characterized by high healthcare expenditure, advanced medical infrastructure, and rapid adoption of minimally invasive surgical techniques. The United States dominates the regional market, accounting for over 85% of revenue share, driven by factors including high prevalence of hemorrhoidal disease (affecting approximately 10 million Americans annually), favorable reimbursement policies, and presence of major medical device manufacturers like Medtronic and Boston Scientific. Recent FDA approvals for advanced treatment modalities, such as THD Doppler-guided hemorrhoidal artery ligation systems, have further stimulated market growth. Canada's market is growing steadily due to increasing awareness and public healthcare coverage of hemorrhoid treatments.
Europe
Europe represents the second largest market for hemorrhoid treatment devices, with Germany, France, and the UK leading in adoption rates. The region benefits from established universal healthcare systems that cover most hemorrhoid treatment procedures. Stringent EU medical device regulations (MDR) ensure high product quality but create longer approval timelines for new devices. The market is shifting toward office-based procedures like rubber band ligation and infrared coagulation due to their cost-effectiveness compared to traditional hemorrhoidectomies. However, price sensitivity in Southern and Eastern European countries somewhat limits adoption of premium-priced devices. The UK's National Health Service recently updated its guidelines to recommend less invasive treatments as first-line options, accelerating market transformation.
Asia-Pacific
As the fastest growing regional market, Asia-Pacific is experiencing double-digit annual growth in hemorrhoid treatment devices, propelled by rising healthcare expenditure, increasing medical tourism, and growing awareness about treatment options. China and India collectively account for over 60% of regional demand, though treatment approaches vary significantly between urban hospitals (adopting advanced devices) and rural clinics (still reliant on traditional methods). Japan maintains a sophisticated market with early adoption of technologies like Doppler-guided hemorrhoid artery ligation systems. Cultural taboos around anal health discussions in some countries continue to present challenges, though disposable incomes and healthcare access improvements are gradually overcoming these barriers. The region also serves as a manufacturing hub for cost-effective treatment devices exported globally.
South America
The South American market shows moderate but consistent growth, with Brazil generating nearly half of regional revenue. Increasing obesity rates and sedentary lifestyles contribute to rising hemorrhoid prevalence. While economic fluctuations affect healthcare spending patterns, the growing middle class is driving demand for improved treatment options. Local manufacturers compete on price, while multinational companies focus on premium offerings in major urban centers. Reimbursement policies vary widely between countries, with Chile and Argentina having more comprehensive coverage than others in the region. The adoption of newer treatment devices remains concentrated in private healthcare facilities catering to affluent populations.
Middle East & Africa
This region presents a bifurcated market landscape, with Gulf Cooperation Council (GCC) countries at the forefront of advanced hemorrhoid treatment adoption, while other areas lag due to healthcare infrastructure limitations. The UAE and Saudi Arabia are investing heavily in specialist colorectal centers, attracting medical tourists seeking high-end procedures. Price sensitivity remains a key factor across most markets, though increasing health insurance penetration is expanding access to modern treatments. Local manufacturing is minimal, creating dependence on imports. Africa shows vast unmet needs, with hemorrhoid treatments largely limited to basic surgical options in urban hospitals. Public health initiatives are gradually improving awareness, but affordability constraints persist across most of the continent.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> The global Treatment Devices for Hemorrhoid Market was valued at US$ 847.3 million in 2024 and is projected to reach US$ 1.42 billion by 2032, at a CAGR of 6.8% during the forecast period 2025-2032.
-> Key players include Medtronic, Ethicon (Johnson & Johnson), Boston Scientific, Micro-Tech Endoscopy, ConMed, Cook Medical, Rocket Medical, THD SpA, and Integra LifeSciences Corporation.
-> Key growth drivers include rising prevalence of hemorrhoids, increasing geriatric population, technological advancements in minimally invasive procedures, and growing healthcare expenditure globally.
-> North America holds the largest market share (38.5% in 2024), while Asia-Pacific is expected to witness the fastest growth during the forecast period.
-> Emerging trends include development of painless treatment options, increasing adoption of disposable devices, and integration of AI in diagnostic procedures.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates